Meningioma Patient Guide

Understanding Your Diagnosis, Treatment, and Recovery

Being told you have a meningioma can feel overwhelming. This guide is written to help you understand what a meningioma is, what your options are, and what to expect at every stage — from diagnosis through recovery and long-term follow-up.

1. What is a Meningioma?

A meningioma is a tumour that grows from the meninges — the three layers of protective tissue (dura mater, arachnoid, and pia mater) that surround the brain and spinal cord. Meningiomas are the most common primary brain tumour in adults, accounting for roughly 37% of all brain tumours.

The vast majority of meningiomas are benign (non-cancerous). The World Health Organization (WHO) classifies them into three grades:

• WHO Grade 1 (Benign): Accounts for about 80% of cases. Grows slowly and rarely spreads. Most patients do very well with appropriate treatment.
• WHO Grade 2 (Atypical): Grows more quickly and has a higher chance of coming back after treatment. Accounts for roughly 15–20% of cases.
• WHO Grade 3 (Malignant/Anaplastic): Rare, accounting for fewer than 5% of cases. Grows aggressively and requires more intensive treatment.

It is important to understand that “brain tumour” does not automatically mean cancer. A Grade 1 meningioma, while serious and requiring careful management, behaves very differently from a malignant tumour.

2. What Causes Meningioma?

In most people, no single cause is identified. Current research points to several known risk factors:

• Previous radiation to the head: People who received radiation therapy to the scalp or brain — including historical low-dose radiation for tinea capitis (ringworm) — have a higher lifetime risk.
• Neurofibromatosis Type 2 (NF2): This genetic condition is associated with multiple meningiomas and bilateral acoustic neuromas.
• Female hormones: Meningiomas are twice as common in women, and some tumours express receptors for oestrogen and progesterone, though the direct link to hormone use remains under study.
• Age: Risk increases with age, with most diagnoses occurring in adults over 50.
• Head injury: Historical studies have suggested a possible link, though the evidence is not conclusive.

The absence of an identifiable cause is not unusual and should not cause additional distress.

3. Symptoms to Watch For

Symptoms depend heavily on where the meningioma is located and how large it has grown. Many small meningiomas cause no symptoms at all and are discovered incidentally on scans done for other reasons.

• Convexity meningiomas (on the outer surface of the brain): Headaches, seizures, weakness or numbness on one side of the body.
• Skull base meningiomas (at the base of the skull): Vision changes, double vision, hearing loss, facial numbness, or difficulty swallowing — depending on which cranial nerves are affected.
• Parasagittal / falcine meningiomas (near the midline): Leg weakness, changes in bladder control, personality or memory changes.
• Spinal meningiomas: Back pain, arm or leg weakness, altered sensation, and in severe cases, loss of bladder or bowel control.

A slowly growing tumour may produce very gradual, subtle symptoms over months or years before diagnosis.

4. How is Meningioma Diagnosed?

MRI with contrast (gadolinium) is the gold standard for diagnosing meningioma. On a contrast MRI, most meningiomas show a characteristic bright, homogenous enhancement with a “dural tail” — a finding that is highly specific to this tumour type.

Additional imaging may include:

• CT scan: Useful for identifying calcification within the tumour and assessing involvement of the surrounding bone.
• CT or conventional angiography: Used for large or highly vascular meningiomas to map blood supply before surgery, and sometimes to perform pre-operative embolisation (blocking the blood supply) to reduce surgical blood loss.
• MR spectroscopy or perfusion imaging: Occasionally used to help distinguish meningioma from other tumour types.

A biopsy is not always needed before treatment, as the imaging appearance is usually diagnostic. However, for atypical cases or when the diagnosis is uncertain, a tissue sample may be obtained.

5. Treatment Options Explained

Not every meningioma requires immediate treatment. Your neurosurgeon will discuss one of three main approaches:

Watchful Waiting (Active Surveillance)

Recommended for small, incidental, asymptomatic meningiomas — particularly in older patients or those with significant medical comorbidities. Regular MRI scans (typically every 6–12 months initially) monitor for growth. Many small meningiomas remain stable for years.

Surgery (Craniotomy)

The primary treatment for symptomatic meningiomas or those showing growth. The aim is safe maximal resection. Surgeons use the Simpson Grading System to describe how completely the tumour was removed:

• Simpson Grade I: Complete removal including the affected dura and bone — lowest recurrence risk.
• Simpson Grade II: Complete tumour removal with dural coagulation.
• Simpson Grade III: Complete tumour removal without dural treatment.
• Simpson Grade IV: Subtotal (partial) removal — higher recurrence risk, but sometimes necessary to protect surrounding structures.

In simple terms: the more completely the tumour is removed, the lower the chance of it returning — but safety always comes first.

Stereotactic Radiosurgery (SRS)

Options include Gamma Knife, CyberKnife, or linear accelerator-based SRS. This is not conventional surgery — it uses precisely focused beams of radiation to treat the tumour without a scalp incision. It is highly effective for small to medium meningiomas (typically under 3 cm) or residual tumour after surgery. Results show excellent long-term tumour control in Grade 1 meningiomas.

6. Preparing for Surgery

Your surgical team will give you specific instructions. In general:

• Stop blood thinners (aspirin, warfarin, clopidogrel, novel anticoagulants) as directed — usually 5–7 days before surgery. Never stop these without guidance.
• Stop smoking at least 4 weeks before surgery to reduce anaesthetic and wound healing risks.
• Fasting: Nothing to eat or drink from midnight before surgery (unless advised otherwise).
• Medications: Take your regular morning medications with a small sip of water unless told to withhold them.
• What to bring: Comfortable loose-fitting clothing, your medication list, insurance documents, and personal items for a 3–5 night hospital stay.

On the day of surgery, you will meet the anaesthetic team, have pre-operative marking, and be taken to theatre. The operation itself typically takes 3–6 hours depending on tumour size and location.

7. What to Expect After Surgery

Immediately after surgery: You will wake up in the recovery room or intensive care unit (ICU) for close monitoring. Headache, fatigue, and nausea are common. Neurological observations (movement, speech, pupils) are performed frequently.

Hospital stay: Most patients spend 3–5 days in hospital. This may be longer if rehabilitation input is needed.

Going home checklist:

• Wound care instructions and follow-up appointment date
• Prescription for anti-seizure medication (if applicable)
• Activity restrictions (no driving until cleared, no heavy lifting for 6 weeks)
• Emergency contact numbers and clear instructions on when to seek urgent care

8. Recovery Timeline

• Week 1–2: Rest, fatigue is normal. Keep the wound clean and dry. Short gentle walks are encouraged.
• Week 3–4: Gradual increase in activity. Many patients feel more alert and energetic. Headaches typically improve.
• Month 2–3: Most patients return to desk work. Driving is usually permitted after neurosurgeon clearance (often 4–6 weeks post-op, subject to seizure history and local regulations).
• Month 3–6: Return to more physical activities, exercise, and most normal daily routines.
• 6–12 months: Full recovery for most patients. Neurological deficits, if present, may continue to improve for up to 12 months.

9. Follow-Up Care

MRI follow-up schedules are determined by WHO grade and completeness of resection:

• Grade 1, complete resection: MRI at 3–6 months post-op, then annually for 5 years, then every 2–3 years.
• Grade 2: More frequent imaging — typically every 6 months for 2 years, then annually.
• Grade 3: Close follow-up in coordination with neuro-oncology.

Signs of recurrence to report promptly: New or worsening headaches, new seizures, changes in vision, speech or limb weakness, or any symptom similar to your original presentation.

10. Questions to Ask Your Surgeon

1. What grade is my meningioma, and what does that mean for my prognosis?
2. Is watchful waiting appropriate for me, or do you recommend treatment now?
3. What is the goal of surgery — complete removal or debulking?
4. What neurological risks are specific to my tumour’s location?
5. How long do you expect surgery to take, and what will my ICU stay involve?
6. Will I need radiation after surgery?
7. When can I return to work and driving?
8. How often will I need follow-up MRI scans?
9. What are the signs of recurrence I should watch for?
10. Where can I access support resources and patient groups?

Schedule Your Consultation

If you have been diagnosed with a meningioma or have concerns about your imaging results, a specialist consultation will help clarify your situation and your options.

Dr Nor Faizal is an Oxford-trained neurosurgeon with subspecialty expertise in brain tumour surgery, including meningiomas at all locations and grades.

Back to Patient Guides